Altamira Therapeutics provides update on Nasdaq listing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 04 2024
0mins
Nasdaq Compliance Issue: Altamira Therapeutics received a notice from Nasdaq stating it no longer meets the minimum bid price requirement of $1.00 per share, as its stock has been below this threshold for 30 consecutive business days.
Appeal Process: The company plans to appeal the determination to a hearing panel, which will temporarily halt any suspension or delisting actions while the appeal is considered, though there is no guarantee of a favorable outcome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
